Larkspur Biosciences

62 posts

Larkspur Biosciences banner
Larkspur Biosciences

Larkspur Biosciences

@LarkspurBio

Destroying tumors by targeting cancer cell fitness.

Cambridge, MA Katılım Aralık 2022
29 Takip Edilen34 Takipçiler
Larkspur Biosciences
Larkspur Biosciences@LarkspurBio·
Announcing the first participant has been dosed in the Ph1 study for LRK-4189, a 1st-in-class targeted protein degrader of the lipid kinase PIP4K2C for the treatment of microsatellite stable (MSS) colorectal cancer (CRC). Learn more bit.ly/3MePHZR
Larkspur Biosciences tweet media
English
0
0
0
43
Larkspur Biosciences
Larkspur Biosciences@LarkspurBio·
Don't miss @drughunter_com 's case study of our lead candidate, LRK-4189. ➡️ bit.ly/4pNgHPr #biotech #cancerresearch #colorectalcancer
drug hunter@drughunter_com

LRK-4189: A Potential First-in-Class PIP4K2C Degrader Heads to the Clinic | drughunters.com/474hvrI PIP4K2C has minimal catalytic activity, but reported scaffolding roles make it well-suited for targeted degradation. Building on insights from tool inhibitors and an academic degrader, Larkspur optimized a CRBN-recruiting molecule, LRK-4189, now planned for first-in-human study in MSS colorectal cancer. Ex vivo CRC spheroid responses, supportive once-daily PK/PD, and xenograft proof-of-concept underpin the program. Read it on Drug Hunter: drughunters.com/474hvrI

English
0
0
1
28
Larkspur Biosciences
Larkspur Biosciences@LarkspurBio·
While at the #NYSE for a Biotech CEO Sisterhood event, CEO Catherine Sabatos-Peyton discussed our cancer cell fitness approach with @BiotechTV’s @bradloncar. ➡️ Watch the full video at: bit.ly/3I9YoCZ #Cancer #Biotech #CancerResearch
BiotechTV@BiotechTV

𝐁𝐢𝐨𝐭𝐞𝐜𝐡 𝐂𝐄𝐎 𝐒𝐢𝐬𝐭𝐞𝐫𝐡𝐨𝐨𝐝 𝐚𝐭 𝐍𝐘𝐒𝐄: Catherine Sabatos-Peyton is leading @LarkspurBio, a company targeting cancer cell fitness. Full video: biotechtv.com/post/larkspur-…

English
0
0
6
632
Larkspur Biosciences
Larkspur Biosciences@LarkspurBio·
Thanks to @MaverickNY of Biotech Strategy Blog for her insightful take on why PIP4K2C stands out as a cancer fitness target and how LRK-4189, our 1st-in-class degrader of this lipid kinase, has the potential to treat MSS CRC. #Biotech #Cancer
Sally Church@MaverickNY

Time to talk turkey on how protein degradation may be a useful strategy for tackling a dark lipid kinase & overcome acquired resistance in CRC. Nice story from @LarkspurBio tinyurl.com/ynftnd7y

English
0
1
6
1.3K
Larkspur Biosciences
Larkspur Biosciences@LarkspurBio·
Announcing the discovery of LRK-4189, a 1st-in-class degrader of the lipid kinase PIP4K2C for the treatment colorectal cancer (CRC). We presented at the MEDI First Time Disclosures: Breakthroughs on New Medicines session at #ACSFALL2025. bit.ly/4lCSVCm #Cancer
Larkspur Biosciences tweet media
English
0
0
2
192
Larkspur Biosciences
Larkspur Biosciences@LarkspurBio·
This #NationalCancerResearchMonth, we’re planning for the first clinical trial evaluating our lead candidate & feeling invigorated after sharing data at #AACR. We're proud to be a part of the cancer research community, turning scientific advancements into breakthrough treatments.
Larkspur Biosciences tweet media
English
0
0
1
81
Larkspur Biosciences
Larkspur Biosciences@LarkspurBio·
At Larkspur Bio, we believe in the power of community. We’re grateful to stand with @ls_cares and help make a meaningful impact this holiday season. Many thanks to our team, which collected contributions for the gift card drive for nonprofit partners. Happy holidays to all!
Larkspur Biosciences tweet media
English
0
0
1
43
Larkspur Biosciences
Larkspur Biosciences@LarkspurBio·
Earlier this fall, our team volunteered to pack curriculum supplies for the Science Club for Girls. We’re grateful for opportunities like this to help more girls and gender-expansive youth discover the wonders of #STEM. #culture #biotech
English
0
1
1
64
Larkspur Biosciences
Larkspur Biosciences@LarkspurBio·
Larkspur CEO, @SabatosPeyton, will share her perspective on the impact of the #InflationReductionAct on innovation in drug development at a @Lumanity webinar tomorrow. Register at bit.ly/3UK1UH6 #biotech #drugdiscovery
Lumanity@lumanity

There's still time to register for next week's #InflationReductionAct webinar bringing together perspectives from #patientadvocacy groups and #biotech professionals to discuss the emerging concerns and explore actionable strategies buff.ly/3CeKQTu #IRA #DrugDevelopment

English
0
1
0
68
Larkspur Biosciences
Larkspur Biosciences@LarkspurBio·
Don’t miss our @sitccancer presentations on key tumor fitness targets: * new data on our 1st-in-class PIP4K2C protein degrader * Pin1 degradation as a promising treatment * how our ML-enabled immune evasion signature models can predict responses to cancer therapy #SITC2024
Larkspur Biosciences tweet media
English
0
1
2
85
Larkspur Biosciences
Larkspur Biosciences@LarkspurBio·
Our Pin1 findings and first-in-class degrader program advance understanding of Pin1’s role in fibroblasts AND cancer cells within #cancer. We will also present how our ML-enabled immune evasion signature models can predict responses to cancer therapies. #cancerresearch #SITC24
English
0
0
1
47
Larkspur Biosciences
Larkspur Biosciences@LarkspurBio·
#SITC2024: We’re thrilled to share new data on the therapeutic potential of tumor fitness targets PIP4K2C & Pin1. Our PIP4K2C preclinical study shows that our 1st-in-class protein degrader can specifically target PIP4K2C & reduce tumor growth in CRC patient samples. @sitcancer
English
1
2
4
807

Keşfet

@sitcancer @drughunter_com @BiotechTV @bradloncar @MaverickNY @AmerChemSociety @AACR @SabatosPeyton